|
Vaccine Detail
AGS-003-BLD Vaccine |
Vaccine Information |
- Vaccine Name: AGS-003-BLD Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: CD40 ligand (CD40L) and patient-specific bladder cell carcinoma (BCC) tumor-associated antigens (TAAs) (NCIT_C129522)
- Immunization Route: Intradermal injection (i.d.)
- Description: This vaccine is composed of autologous, mature dendritic cells (DCs) are electroporated with in vitro transcribed (IVT) RNAs encoding for a synthetic form of T-cell protein CD40 ligand (CD40L) and IVT RNA encoding for autologous tumor-associated antigens (TAAs) derived from patient-specific bladder cell carcinoma (BCC) cells, with potential immunostimulatory and antineoplastic activities. The RNA is translated and processed, and BCC-specific antigenic peptides are subsequently presented via major histocompatibility complex (MHC) Class I molecules on the DCs surface. The MHC-presented peptides interact with and activate CD8-positive T-cells, which elicits a highly specific cytotoxic T-cell (CTL) response against tumor cells expressing the patient-specific BCC TAAs. The signal cascade initiated by expression of the co-stimulatory molecule CD40L results in the secretion of the inflammatory cytokine IL-12, which further stimulates CTLs. (NCIT_C129522) The vaccine can be used in combination with gemcitabine hydrochloride and cisplatin which stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading, while the vaccine helps the body build an effective immune response to kill tumor cells. In combination, they may make the tumor smaller and reduce the amount of tissue that needs to be removed by surgery in patients with bladder cancer. (NCT02944357)
|
Host Response |
|
References |
NCIT_C129522: Autologous Bladder Cell Carcinoma RNAs/CD40L RNA Electroporated Autologous Matured Dendritic Cells [https://ncithesaurus.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C129522]
NCT02944357: Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery [https://clinicaltrials.gov/study/NCT02944357]
|
|